GLENMARK
664.25
2019-01-04
GLENMARK PHARMACEUTICALS LTD.
Profitability metrics STANDALONE CONSOLIDATED
Asset Turnover 0.4089 0.6978
Current ratio 4.51 2.76
WC days 452.09 223.64
EBITDA (%) 23.85 18.81
FCF (Rs Cr.) -75 199
ROCE (%) 10.54 14.33
ROE (%) 9.76 15.57

Solvency metrics STANDALONE CONSOLIDATED
Cash Ratio 0.08 0.39
Div. payout (%) 5.56 7.02
Int. Coverage 7.38 4.91
LT D/E 0.29 0.9
Solvency Ratio 0.38 0.24

Valuation STANDALONE CONSOLIDATED
Beta 0.5808 0.5808
Div. yield (%) 0 0
EV (Rs Cr.) 17679.8 18280.5
P/BV 1.43 2.88
P/E 14.67 18.5
PEG 0.25 0.41
P/S 2.32 1.64

Balance sheet metrics STANDALONE CONSOLIDATED
BV/share 368.21 182.96
3Y growth BV/s (%) 102 65
Cash (Rs Cr.) 177.38 1234.69
Total Debt (Rs Cr.) 2981 4639
Net block (Rs Cr.) 1699 3030

P&L metrics STANDALONE CONSOLIDATED
DPS 2 2
EPS 35.93 28.49
Net Income (Rs Cr.) 1014 804
Operating profit (Rs Cr.) 1347 1615
No. of o/s shares 28.22 28.22
Revenue (Rs Cr.) 6403 9074
Total Income (Rs Cr.) 6583 9165

Cash Flow metrics STANDALONE CONSOLIDATED
CEPS (%) 3983 2328
3Y growth CEPS 6.44 0.31
CFF (Rs Cr.) -62 543
CFI (Rs Cr.) -1137 -1001
CFO (Rs Cr.) 1124 657
FCF (Rs Cr.) -75 199
3Y growth Op. CF (%) 675 36

Growth metrics STANDALONE CONSOLIDATED
3Y growth dividends (%) 0 0
1Q growth EBITDA (%) 0 0
3Y growth EBITDA (%) 11 63
4Q growth EBITDA (%) 0 0
1Q growth EPS (%) 0 0
3Y growth EPS (%) -3 63
4Q growth EPS (%) 0 0
3Y growth Net inc. (%) 1 69
1Y growth Op. CF (%) 28 0
1Q growth revenue (%) 0 0
3Y growth revenue (%) 23 37
4Q growth revenue (%) 0 0